Detailed Instructions: In this task, you are given a text of many news articles seperated by special token "|||||". Your task is to summarize them.
Q: By Robert Preidt, HealthDay Reporter 
  
 WEDNESDAY, Nov. 25, 2015 (HealthDay News) -- A new form of treatment for type 1 diabetes that's based on the immune system appears safe for patients in an early trial. 
  
 However, only a larger trial will show if the treatment -- which uses immune cells called regulatory T cells (Tregs) -- is effective against the illness, researchers said. 
  
 If the therapy does work out, it "could be a game-changer," study first author Jeffrey Bluestone, a professor of metabolism and endocrinology at the University of California, San Francisco, said in a university news release. 
  
 "For type 1 diabetes, we've traditionally given immunosuppressive drugs, but this trial gives us a new way forward. By using Tregs to 're-educate' the immune system, we may be able to really change the course of this disease," he explained. 
  
 In type 1 diabetes, the immune system attacks insulin-secreting beta cells in the pancreas. Many treatments suppress the immune system, but that can lead to serious side effects, such as increasing a patient's susceptibility to infections or cancer. About 5 percent of all cases of diabetes are type 1 disease. 
  
 According to the researchers, the new therapy uses a patient's own regulatory T cells to protect insulin-producing beta cells in the pancreas. The approach is designed to reduce the immune system's attack on beta cells, while still leaving the immune system strong enough to fight infections. 
  
 The patients in the first U.S. safety trial of the treatment received infusions of as many as 2.6 billion of the protective Treg cells and had no serious side effects, Bluestone's team said. 
  
 The results of the Phase 1 trial were published in the Nov. 25 online edition of the journal Science Translational Medicine. Phase 1 trials typically only examine if a drug or intervention is safe, they are not focused on effectiveness. 
  
 The next phase of this research would be a clinical trial to test the effectiveness of the new therapy, the researchers said. 
  
 Two experts in type 1 diabetes said the approach holds real promise. 
  
 "This is a very novel approach to treatment because it deals with the route cause for type 1 diabetes -- which is destruction of the insulin-producing cells of the pancreas by one's own immune system," said Dr. Deena Adimoolam, assistant professor of medicine, endocrinology, diabetes and bone disease at the Icahn School of Medicine at Mount Sinai in New York City. 
  
 "The use of regulatory T-cells in its early stages of clinical research appears successful," she said, "and I hope that future trials show long-term treatment with minimal side effects." 
  
 Dr. Minisha Sood directs inpatient diabetes care at Lenox Hill Hospital, also in New York City. She said that regulatory T cells "are known to control autoimmunity -- not only in type 1 diabetes but also in a number of other autoimmune diseases. Therefore, it is believed that eventual treatments involving regulatory T cells may slow progression of or reverse the autoimmunity, which is the cause of type 1 diabetes." 
  
 While larger trials are needed to confirm a benefit for patients, the study "did establish that immunotherapy with regulatory T cells is feasible from a safety standpoint, which is very promising," Sood said. 
  
 More information 
  
 The American Diabetes Association has more about type 1 diabetes. 
  
 Copyright © 2015 HealthDay. All rights reserved. 
  
  ||||| Hundreds of thousands of diabetics could potentially be freed from the “daily grind” of insulin injections after research suggested a new treatment was safe. 
  
 Scientists at the University of California, San Francisco, developed a way of restoring the ability of people with type-1 diabetes to produce insulin for a year or more using their own immune cells, The Times newspaper reported. 
  
 A type-1 diabetic’s immune system attacks the pancreas but the researchers cultivated billions of T-regulatory immune cells, known as Tregs, that do not have this trait and gave them to the patients. 
  
 Professor Jeffrey Bluestone, one of the scientists involved in the work, said their findings could be a “game-changer”. 
  
 “For type-1 diabetes, we’ve traditionally given immunosuppressive drugs, but this trial gives us a new way forward,” he said. 
  
 “By using Tregs to re-educate the immune system, we may be able to change the course of this disease.” 
  
 In the first clinical trial of the technique, 14 people were treated without any serious side-effects, the researchers reported in the journal, Science Translation Medicine. They now plan a larger trial. 
  
 The method involves taking a pint of blood from the patient, removing up to 4 million Tregs and then increasing that number by 1,500 times in a test tube. 
  
 They are then returned to the patient and do not attack the pancreas. Up to 25 per cent were found to be still there after 12 months. 
  
 The procedure could potentially be used to treat other conditions such as rheumatoid arthritis, cardiovascular disease and even obesity. 
  
 “Using a patient’s own cells - identifying them, isolating them, expanding them, and infusing them back - is an exciting new pillar for drug development,” Professor Bluestone said. 
  
 One of the patients in the trial, Mary Rooney, 39, said: “The work of Dr Bluestone and his team offers new hope for people with type-1 diabetes. 
  
 “The Treg intervention aims to prevent the development and progression of type-1 diabetes, freeing people like me from the daily grind of insulin therapy and lifelong fear of complications.” ||||| Thank you for your interest in spreading the word about Science Translational Medicine. 
  
 NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. ||||| In the first U.S. safety trial of a new form of immunotherapy for type 1 diabetes (T1D), led by UC San Francisco scientists and physicians, patients experienced no serious adverse reactions after receiving infusions of as many as 2.6 billion cells that had been specially selected to protect the body's ability to produce insulin. 
  
 T1D is an autoimmune disease in which the immune system, which normally defends against infections, somehow goes awry and targets insulin-secreting cells, called beta cells, in the pancreas. Many T1D therapies aim to tackle this problem by suppressing the immune response, but that approach can have serious consequences, including an increased susceptibility to infection or cancer. 
  
 As reported in the Nov. 25, 2015, online issue of Science Translational Medicine, however, the cells used in the completed Phase 1 trial, known as regulatory T cells (Tregs; pronounced "tee-regs"), are instead based on the concept of "immune tolerance" - these cells have the potential to dampen the immune system's assault on beta cells while leaving its infection-fighting capabilities intact. 
  
 "This could be a game-changer," said first author Jeffrey A. Bluestone, PhD, the A.W. and Mary Margaret Clausen Distinguished Professor in Metabolism and Endocrinology at UCSF. "For type 1 diabetes, we've traditionally given immunosuppressive drugs, but this trial gives us a new way forward. By using Tregs to 're-educate' the immune system, we may be able to really change the course of this disease." 
  
 The encouraging safety results from the trial, conducted at UCSF by Stephen E. Gitelman, MD, professor of pediatrics, and at Yale School of Medicine by Kevan C. Herold, MD, "support the development of a Phase 2 trial to test efficacy of the Treg therapy," the research team writes. 
  
 The infused Tregs used in the trial were derived from the trial participants' own cells, using an ex vivo (outside the body) "isolation and expansion" technique first described by Bluestone and colleagues in 2009. 
  
 In this procedure, doctors remove less than two cups of blood, which in T1D patients usually contain between 2 and 4 million of the desired Tregs, commingled with millions of cells of other types. Using a method known as fluorescence-activated cell sorting (FACS), which precisely segregates cells based on molecules they display on their surface, the therapeutic Tregs are separated and then placed into a growth medium in which they can attain a 1,500-fold increase in number. 
  
 Bluestone and colleagues have shown in previous work that Tregs recovered after this expansion are more functionally active, can repair defects in the immune system of patients with T1D and are more likely to survive long-term in the body than Tregs produced by other means. 
  
 The trial marked the first U.S. study in which large populations of Tregs created using these techniques were infused back into patients' circulation. Fourteen patients from 18 to 43 years old, all with recent-onset T1D, were organized into four groups that successively received infusions containing greater numbers of Tregs: members of the first group received about 5 million cells, and the fourth group about 2.6 billion cells. 
  
 In addition to being well tolerated by all four groups, the treatments were durable, with up to 25 percent of the infused therapeutic cells still detectable in patients' circulation a year after they had received just a single infusion. 
  
 The positive safety results from the trial are particularly reassuring, because in some instances T cells that were therapeutically introduced in cancer treatment have caused patients' immune systems to spiral out of control. Based on the Phase 1 data from this trial, New Jersey-based Caladrius Pharmaceuticals is now in the early stages of planning a Phase 2 trial of Tregs for T1D. 
  
 Trial participant Mary Rooney, 39, who was diagnosed with T1D four years ago, said she has experienced no side effects from Treg treatment. "The work of Dr. Bluestone and his team offers new hope for people with type 1 diabetes and other autoimmune disorders," Rooney said. "The Treg intervention aims to prevent the development and progression of type 1 diabetes, freeing people like me from the daily grind of insulin therapy and lifelong fear of complications. It's truly groundbreaking research with enormous potential." 
  
 In addition to their potential value as a diabetes therapy, said Bluestone, a member of the UCSF Diabetes Center, Tregs hold great promise as treatments for other autoimmune diseases such as rheumatoid arthritis and lupus, and even as therapies for cardiovascular disease, neurological diseases and obesity. 
  
 UCSF research on Tregs and other novel approaches to autoimmune diseases recently received a significant boost from the Parker Foundation, established this year by Silicon Valley entrepreneur and philanthropist Sean Parker. In November, the foundation donated $10 million to establish the Sean N. Parker Autoimmunity Research Laboratory, with Bluestone as the laboratory's inaugural director. 
  
 "Using a patient's own cells - identifying them, isolating them, expanding them, and infusing them back into the patient - is an exciting new pillar for drug development," said Bluestone, "and we expect Tregs to be an important part of diabetes therapy in the future." 
  
 Explore further: Immune cell subset in mouse model of disease promotes healing and reduce inflammation 
  
 More information: "Type 1 diabetes immunotherapy using polyclonal regulatory T cells," by J.A. Bluestone, Science Translational Medicine, stm.sciencemag.org/lookup/doi/10.1126/scitranslmed.aad4134 
  
  |||||
A:
A new treatment going through clinical trials could mean the end of daily insulin injections for diabetics—and could even have huge benefits for people suffering from arthritis, cardiovascular diseases, and obesity, the Independent reports. "This could be a game-changer," one University of California, San Francisco, researcher says in a press release. "We may be able to really change the course of this disease." Basically, researchers figured out how to get people with type 1 diabetes to produce their own insulin for a year or longer, the Independent reports. Results from the new treatment's first clinical trial—which found no serious side effects in 14 volunteers—were published Wednesday in Science Translational Medicine. Researchers caution, however, that larger tests are needed to back up the results, notes HealthDay. When a person has type 1 diabetes, their immune system begins to target beta cells that produce insulin, according to the press release. The new treatment uses things called T-regulatory immune cells—or Tregs—which can slow the immune system's attack on beta cells while still allowing it to continue fighting infections. Researchers removed up to a pint of blood—along with 2 million to 4 million Tregs—from patients. After putting those Tregs into a growth medium to increase their numbers by 1,500%, they were returned to the patient's body. The Independent reports up to a quarter of those Tregs were still in the volunteers' bodies a year later. Researchers will now prepare a second trial to test the effectiveness of the treatment. A diabetes specialist at Lenox Hill Hospital in New York City who was not affiliated with the study called the results "very promising." (These stats show why this could be a very big deal.)